Toggle navigation
About Us
Science & Innovation
Products and Resources
Our Responsibility
Careers
Investors
Media
Toggle navigation
Press Releases
Featured News
Press Statements
Subscribe
Media Contacts
Press Releases
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Year
All Years
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Category
All Categories
Corporate News
Product News
Vaccines News
Uncategorized
Keywords
Go
Advanced Search
Search
Search Headlines Only
Category
All Categories
Corporate News
Product News
Vaccines News
Uncategorized
From
To
Asset Types
Video
Audio
Photos
Documents
Events
Standard
Jun 2, 2023
New data from Sanofi’s diverse, differentiated oncology pipeline and portfolio to be presented at ASCO 2023
May 21, 2023
Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine
May 18, 2023
Sanofi Applauds Supreme Court Ruling Supporting Scientific Innovation by Striking Down Amgen's Asserted PCSK9 Patent Claims in Amgen v Sanofi
May 5, 2023
New late-breaking data at ATS 2023 demonstrate significant advancements across Dupixent® and broader respiratory pipeline
17 abstracts showcase new data for Dupixent, itepekimab and anti-IL-13/TSLP NANOBODY® molecule in COPD and asthma
May 1, 2023
Sanofi Canada et Diabetes Care Community annoncent une collaboration pour soutenir le parcours de bien-être émotionnel des Canadiens et Canadiennes vivant avec le diabète
Apr 27, 2023
Sanofi completes acquisition of Provention Bio, Inc.
Apr 4, 2023
Sanofi Breaks Ground on State-of-the-Art Facility in Swiftwater for Sustainable Production of Pandemic Flu Vaccines
Mar 23, 2023
Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial
First and only biologic to demonstrate clinically meaningful and statistically significant reduction (30%) in exacerbations compared to placebo
Mar 18, 2023
Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis
More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks
Mar 7, 2023
Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review
Show
5
10
25
50
100
per page
«
1
2
3
4
5
6
7
8
9
…
95
»
Print
Email page
RSS